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Abstract
Background: Therapeutic regulation of PPARδ activity using selective agonists has been proposed for various
disorders. However, the consequences of altered peroxisome proliferator-activated receptor delta (PPARδ)
activity in the context of intestinal tumourigenesis remain somewhat unclear. Contradictory evidence suggesting
PPARδ either attenuates or potentiates intestinal neoplasia. To further investigate the PPARδ dependency of
intestinal tumourigenesis, we have analysed the consequences of PPARδ deficiency upon intestinal neoplasia
occurring in mice with impaired mismatch DNA repair.
Methods: Mice deficient for both PPARδ and the mismatch repair gene Mlh1 were produced and the incidence
and severity of intestinal neoplasia recorded.
Results: No significant differences between the control genotypes and the double mutant genotypes were
recorded indicating that deficiency of PPARδ does not modify impaired mismatch repair induced neoplasia.
Conclusion: In contrast with the previously observed acceleration of intestinal neoplasia in the context of the
ApcMin/+ mouse, PPARδ deficiency does not alter the phenotype of mismatch repair deficiency. This data supports
the notion that PPARδ is not required for adenoma formation and indicate that any pro-tumourigenic effect of
PPARδ inactivation may be highly context dependent.
Background
Peroxisome proliferator-activated receptors (PPARs) are
lipid-activated transcription factors exerting several func-
tions in development and metabolism. There are 3 major
PPAR isoforms; α,β/δ and γ and each has distinct agonist
binding properties and different regulation of expression
resulting in distinct distributions [1]. The roles for PPARδ
appear diverse and are not fully characterised, but include
the regulation of lipid uptake, metabolism, and regula-
tion of proliferation and differentiation within many dif-
ferent cell types. Consequently, the therapeutic regulation
of PPARδ activity using selective agonists has been pro-
posed for many varied disorders including: lung cancer
[2], experimental autoimmune encephalomyelitis [3],
skin disorders such as psoriasis and cancer [4], type 2 dia-
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betes [5], metabolic syndrome [6] and dyslipidemias
[7,8].
Although a great deal of evidence exists to show that
PPARδ is potentially important in intestinal tumourigen-
esis, it is currently unclear whether PPARδ attenuates or
potentiates this condition. Several studies have shown
that activation of PPARδ or increased PPARδ levels are
associated with increased intestinal neoplasia in a variety
of tissues [9-13]. Also, two studies have shown that PPARδ
deficiency suppressed or had no role upon tumourigene-
sis [14,15]. Taken together these analyses suggest that
PPARδ potentiates colon carcinogenesis. However, two
independent approaches have recently suggested that
PPARδ expression in vivo is not up-regulated in intestinal
adenomas. Firstly a study of matched human tumour and
normal intestinal tissues found reduced levels of PPARδ
expression in the tumours [16]. Second several studies
using the classical mouse model of intestinal neoplasia
(the ApcMin mouse), found either no change, or reduced
PPARδ expression in colonic adenomas compared to nor-
mal tissues in this model [17-20], while a recent publica-
tion has shown that ligand activation of PPARδ attenuates
chemically induced colon carcinogenesis [20]. Further-
more, it has been demonstrated that PPARδ deficiency
does not suppress intestinal tumourigensis in ApcMin/+
mice, but indeed promotes some aspects of intestinal neo-
plasia [17,20,21]. These data suggest that PPARδ attenu-
ates colon carcinogenesis.
Thus, given the obvious disparity within the published lit-
erature, we have utilized another mouse neoplasia model
to further investigate the role of PPARδ in intestinal
tumourigenesis. Mice possessing null mutations in the
mismatch repair (MMR) gene Mlh1 are prone to develop
different types of neoplasia and present with lymphomas
and intestinal tumours but show increased mutation in all
tissues examined [22]. Likewise, germline mutations in
the human MLH1 gene are involved in Hereditary non-
polyposis colorectal cancer [23]. We have inter-crossed
PPARδ null mice [24] to the mismatch repair defective
Mlh1 null mice [25] and produced cohorts for the differ-
ent combinations of the genotypes in order to investigate
the consequences of impaired MMR induced tumourigen-
esis in the context of PPARδ deficiency.
Methods
Mice were generated from sixth generation C57BL 6 back-
crossed mice. All experiments were performed according
to UK Home Office regulations. Inter-crossing the PPARδ
null mice (PPARδ-/-) to the mismatch repair defective
Mlh1 null mice (Mlh1-/-) produced cohorts containing a
minimum of 16 animals for each genotype combination
of interest (Mlh1-/-PPARδ+/+, Mlh1-/-PPARδ+/-, Mlh1-/-
PPARδ-/-). Littermates were genotyped by PCR on DNA
from tail biopsy and allowed to age and monitored for
signs of intestinal tumours. Animals were harvested when
they displayed overt symptoms of disease, and tumour
burden was ascertained upon dissection.
Results and discussion
Through inter-crossing the PPARδ null mice (PPARδ-/-) to
the mismatch repair defective Mlh1 null mice (Mlh1-/-) we
produced cohorts containing a minimum of 16 animals
for each genotype combination of interest and examined
survival, intestinal adenoma multiplicity and tumour size
at death for each of the cohorts (Figure 1). We find that,
although the mean age at death of Mlh1-/-PPARδ-/- mice
was 248.1 days compared to 203.5 days in controls, this
was not statistically different (Figure 1a, p = 0.34 Log-
Rank test). Furthermore, the predisposition to lymphom-
agenesis was not significantly altered between the Mlh1-/-
PPARδ+/+  and  Mlh1-/-PPARδ-/-  cohorts (Figure 1b). The
possibility remains that there may be subtle effects of
PPARδ deficiency that lie below the detection threshold of
the present study, a possibility that would be resolved by
a substantially increased cohort analysis.
Contrary to the finding from the APCMin/+ PPARδ-/- inter-
cross, which indicated that PPARδ deficiency promotes
some aspects of intestinal neoplasia [17,20,21], no signif-
icant differences were discovered between either number
or size of intestinal adenomas in the Mlh1-/-PPARδ+/+ and
Mlh1-/-PPARδ-/- cohorts (Figure 1c, d). This was confirmed
in both the small intestinal and large intestinal tumours
(P > 0.1, Mann Whitney U test), although notably the
group sizes in both these analyses were small.
To assess the nature of the Mlh1-/-PPARδ+/+ and Mlh1-/-
PPARδ-/- aberrant intestinal tissues, β-catenin immunohis-
ochemistry was performed and again no differences were
observed between the two genotypes (data not shown).
Up-regulation of β-catenin in large intestinal adenomas
was observed in both genotypes. Furthermore in the small
intestine, in addition to lesions displaying increased β-cat-
enin levels, it was also possible to identify a small subset
of lesions that maintain normal levels of β-catenin, a phe-
nomenon previously described within defective MMR
intestine [26]. Thus, the induction of dysplastic lesions
and the deregulation of β-catenin in the intestine occur-
ring as a consequence of defective MMR is not dependent
upon PPARδ status and has no requirement for PPARδ.
We therefore find that loss of PPARδ does not alter
tumour incidence or morphology of tumourigenesis on
the  Mlh1-/- background. Given that MMR deficiency is
considered to lead to a mutator phenotype which thereby
increases the rate of mutation of elements of the Wnt
pathway, our findings argue that PPARδ deficiency does
not enhance or diminish such a mutator phenotype. ByBMC Cancer 2006, 6:113 http://www.biomedcentral.com/1471-2407/6/113
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implication, the increased adenoma formation seen in the
ApcMin/+PPARδ-/-  mutants may arise through PPARδ
dependent modification of the frequency of gene conver-
sion events that are known to underlie the majority of
polyp formation in the ApcMin/+ mouse [27]. Alternatively,
subsequent to the gene conversion events, PPARδ defi-
ciency may alter the resulting cellular signalling/gene
expression pathways which permit cell survival and
tumour progression. Our data again apparently contradict
the observed acceleration of adenoma formation follow-
ing agonist activation of PPARδ[11], as this predicts
reduced adenoma burden in the absence of PPARδ. How-
ever, PPARδ deficiency (as assessed through the PPARδ
null mutation) may not necessarily be functionally oppo-
site of ectopic PPARδ activation as it is possible that any
alteration in the levels of PPARδ activity, whether a reduc-
tion or increase, have different consequences dependant
on the genetic background or indeed tissue being studied.
In terms of evaluating the potential deleterious pro-
tumourigenic effect of PPARδ deficiency, our data suggests
that this only accelerates adenoma formation in certain
defined genetic settings (e.g. ApcMin/+), and does not gen-
erally enhance adenoma formation per se. This genetic
dependency may reflect differences in the mutational
events occurring in the Mlh1 and Apc mutant back-
grounds. By analogy, any potential danger in the thera-
peutic use of PPARδ agonists to activate PPARδ may
critically depend upon subtle changes in the underlying
genetic predisposition.
Conclusion
In summary, we show that PPARδ deficiency does not
alter either lymphomagenesis or adenoma formation in
mice with defective MMR. This data again support the
Survival of and tumour multiplicity within each of the cohort Figure 1
Survival of and tumour multiplicity within each of the cohort. Survival of (A), tumour type (B), intestinal adenoma 
number (C) and size (D) in Mlh1-/-PPARδ+/+, Mlh1-/-PPARδ+/-, and Mlh1-/-PPARδ-/- mice. KaplañMeier plot (A) showing the age of 
each animal at the time of death: Solid line, Mlh1-/-PPARδ+/+ (n = 20); dashed line, Mlh1-/-PPARδ+/- (n = 20); broken line, Mlh1-/-
PPARδ-/- (n = 16). Pie charts (B) indicate the type identified at death in each mouse. Grey slice, mice with lymphoma; white slice, 
mice with akanthoma; striped slice, mice with dysplastic cysts; black slice, mice with Hemangiosarcomas. Box plots showing the 
number (combining small and large intestine) (C) or size (D) of intestinal adenomas per mouse at death. Intestinal preparations 
were collected from animals, fixed and tumours in the small and large intestine were counted and sized (expressed as width by 
length). Boxes encompass the first quartile (at bottom) to the third quartile (at top) of the data set; the horizontal boxed line 
represents the median; the asterisks represent outliers.
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notion that PPARδ is not required for adenoma formation
and indicate that any pro-tumourigenic effect of inactiva-
tion may be highly context dependent. Thus, in the con-
text of a defective MMR environment, PPARδ agonism is
unlikely to be pro tumourigenic.
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